Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
InMed Pharmaceuticals ( (INM) ) has issued an announcement.
On December 12, 2025, InMed Pharmaceuticals announced that the recently signed H.R. 5371 Act in the United States could materially negatively impact its subsidiary, BayMedica Inc., by prohibiting certain aspects of its commercial business related to rare, non-intoxicating cannabinoids. Despite this, InMed’s core pharmaceutical programs, including treatments for Alzheimer’s and age-related macular degeneration, remain unaffected and continue to progress under FDA guidance.
The most recent analyst rating on (INM) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Underperform.
InMed Pharmaceuticals’ overall stock score is primarily hindered by its financial performance and valuation concerns. The persistent operational losses and negative cash flows are significant risks. Technical analysis indicates a mildly bearish to neutral trend. The recent $5M private placement is a positive development, but it does not outweigh the broader financial challenges.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals is a pharmaceutical drug development company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications.
Average Trading Volume: 351,560
Technical Sentiment Signal: Sell
Current Market Cap: $4.01M
See more data about INM stock on TipRanks’ Stock Analysis page.